Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP7 (mavoglurant) and Intravenous Cocaine Interaction Study
NCT06273540Phase 1Completed
- Sponsor
- STALICLA
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cocaine use disorder (CUD) comparing STP7 (mavoglurant) with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Heart Rate response at Day 10 and 2 more. Started Apr 2024; status: completed.
02
Drugs
mavoglurant
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT06273540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273540.